Supervised Consumption of Methadone and Buprenorphine by Community Pharmacists

Service Specification
Operational from: 1st April 2014

Review date: 31st March 2015
Contents

Introduction ......................................................................................................... 3
The Role of the Pharmacist ............................................................................... 4
Methadone Substitution ........................................................................................ 4
Buprenorphine Substitution .................................................................................. 5
The Need for a Supervised Methadone & Buprenorphine Consumption Programme.. 6
Methadone....................................................................................................... 6
Buprenorphine.................................................................................................. 6
Aims & Objectives of the Scheme ........................................................................ 8
Operational Procedures ........................................................................................ 9
Accepting new clients into Supervised Consumption ............................................ 9
Client/Pharmacy Agreement ........................................................................... 10
Identification of clients .................................................................................... 10
Controlled drugs prescriptions ........................................................................... 10
Preparation of medication ............................................................................... 12
Discreet and efficient supervision by Pharmacist ............................................... 12
Disposal of waste ........................................................................................... 13
Maintenance of patient records ........................................................................ 13
Concerns regarding presenting clients .............................................................. 13
Liaison ........................................................................................................... 16
Premises ........................................................................................................ 16
Payments ....................................................................................................... 17
Application To Join The Pharmacist Supervised Consumption Scheme .......... 18
Leaving the scheme ........................................................................................... 18
Appendices ........................................................................................................ 19
Appendix 1 - Models of Care Pathway ................................................................. 20
Appendix 2 - RPS Press release and NPA model protocol .................................... 22
Appendix 3 - Application to Join the Scheme ...................................................... 23
Appendix 4 - Patient Identification Form ............................................................ 24
Appendix 5 - Client/pharmacy agreement ............................................................. 25
Appendix 6 - Client leaflet – Subutex/buprenorphine ............................................ 29
Appendix 7 - Record of Treatment ..................................................................... 30
Appendix 8 - Pharmacy Claim Form .................................................................. 29
Appendix 9 - When to Contact the Prescriber ...................................................... 30
Appendix 10 - Pharmacist - Prescriber Contact Form ............................................ 31
Appendix 11 - Changes in the provision of Supervised Consumption of Methadone or Buprenorphine by Accredited Pharmacists .................................................. 32
Resources ......................................................................................................... 35
Application to Join the Scheme........................................................................ 34
Patient Identification Form ............................................................................ 37
Pharmacist - Prescriber Contact Form .............................................................. 38
Pharmacy Claim Form ...................................................................................... 39
Changes in the provision of Supervised Consumption of Methadone or Buprenorphine by Accredited Pharmacists .......................................................... 40
Additional Information ...................................................................................... 41
Clinical Guidelines ............................................................................................ 41
Guidance for the Use of Buprenorphine for the Treatment of Opioid Dependence in Primary Care ................................................................. 41
Medico-legal aspects ......................................................................................... 41
Introduction

The guidelines below outline the background to and the Standard Operational Procedures and administrative processes for Blackburn with Darwen Borough Council Public Health Supervised Consumption Scheme for Methadone and Buprenorphine. This document also contains an application form for those interested in joining the scheme (See page 36).

The supervised consumption of methadone and Buprenorphine is a local Improvement Service under the ‘Contractual Framework for Community Pharmacy’ and as such participation by community pharmacists in this service remains voluntary and guided by localised need. However, those who join the scheme will have a contractual obligation to adhere to this specification and to input as appropriate into the ‘shared care’ of substance users.

Pharmacists participating in this service will be expected to take on the number of clients that they feel appropriate for their pharmacy within the parameters of good practice advised by the local Drug Services, taking into account all their community responsibilities.

Models of Care, introduced by the National Treatment Agency in 2002 outlines a four tier system of service provision based on the principles of National Service Frameworks. The aim is to provide treatment through integrated care pathways across these four tiers. Pharmacists are regarded as a tier one service in Blackburn with Darwen, a non-substance misuse specific service, but which offers advice and support to substance users. The Models of Care pathway developed for Supervised Consumption of Methadone and Buprenorphine is shown in Appendix 1.

One key element of drug treatment for opiate users is the prescribing of Methadone or Buprenorphine. (NICE Technology Appraisal 114: Methadone and buprenorphine for the management of opioid dependency (January, 2007). Studies have shown that Methadone Maintenance Treatment reduces levels of injecting drug use and associated health problems, acquisitive crime and drug related death among those in treatment. Thus the Clinical Guidelines believe it to be ‘an important part of drug misuse services’ (DoH, 2007). Prescribing substitute medications allows time for individuals to implement personal or social changes that can reduce the impact of their illicit drug use and is a key element to increase the opportunities of individuals to achieve their goals.

In Blackburn with Darwen, Greater Manchester West (GMW) manages the opiate substitution treatment service, which includes the GPs signed up for Locally Enhanced Services and Criminal Justice Services. This scheme for supervised consumption of methadone and buprenorphine applies only to supervised consumption requested by prescribers at GMW, GPs on the shared care scheme (Locally Enhanced Service) and Lifeline (Young Persons Prescribing Service).

Contact Details:

Medicines Management (CCG)  Julie Kenyon  01254 282090
GMW Drug Service  Susan Bishop  01254 226062
PH commissioning lead  Karen Cassidy  01254 585425
Lifeline:  Zoe Gatland  01254 677493
The Role of the Pharmacist

Pharmacists play a key and unique role in the care of the substance users. ‘Key’, in that through the supervision of consumption of methadone or buprenorphine, the pharmacist is instrumental in supporting drug users in complying with their prescribed regime, therefore reducing incidents of accidental death through overdose. Also through supervision, pharmacists are able to keep to a minimum the misdirection of controlled drugs, which may help to reduce drug related deaths in the community.

The ‘unique’ role that pharmacists play in the treatment of drug users is the daily contact that they have with their patients, and their ability to monitor and offer advice on the patient’s general health and wellbeing. By integrating pharmacists into the ‘shared-care’ service this ‘gateway’ role can be developed to maximise the positive impact treatment has for patients.

An important consideration however is that adhering to daily supervision regimes reduces opportunities for individuals to integrate back into society through employment, education, holidays etc. It is important that once the patient is stabilised and feeling confident, that the opportunity to increase their take home doses is fully considered. In line with the ‘Drug Misuse and Dependence – Guidelines on Clinical Management’ take home doses are unlikely to be provided for the first three months. At times of crisis or relapse, supervision may need to be temporarily re-instated. This should not be seen as a failure, as making changes to drug use and habitual behaviours can be a lengthy process with ‘lapsing’ a common feature.

It is therefore important that the patient attends the same pharmacy with each new prescription and that the pharmacist is supportive with an understanding attitude. The relationship between patient and pharmacist should ideally be friendly, but professional.

Methadone Substitution

Methadone is a long acting agonist for opioid receptors. One oral dose per day can eliminate the need for opiates but there may still be a craving for opiates and for injecting. Methadone is most frequently prescribed as methadone mixture 1mg/ml, which is unlikely to be injected. The half-life of methadone is approximately 1-2 days. This makes it particularly suitable for once daily dosing.

Methadone maintenance treatment has been shown to have a protective effect, reducing overdose among those in treatment. It is also linked to reductions in crime IV use and injecting related harm. Patients stabilised on methadone should be alert and coherent.
Methadone is a schedule 2 drug subject to full controlled drug requirements relating to prescriptions, safe custody, the need to keep registers etc.

Buprenorphine Substitution

Buprenorphine is available in 0.4mg, 2mg and 8mg sublingual tablets. The tablets are administered sublingually because it has poor oral bioavailability – inactivated by gastric acid and a high first pass metabolism.

Buprenorphine is a mixed agonist/antagonist. It partially activates the mu opioid receptors whilst exerting sufficient opiate effects to prevent or alleviate withdrawal. It has a high affinity for the mu receptors and binds more tightly than methadone or heroin. It also binds strongly to the kappa opioid receptors where it acts as an opioid antagonist. In doing so it reduces the effects of using opiates on top of buprenorphine.

Buprenorphine is relatively safe during pregnancy and breastfeeding with less frequent, less severe and shorter neonatal withdrawal than with methadone. It may be better suited to those wishing to cease heroin use.

The RCGP (2004:2) recognises that:

There is a growing body of evidence that treatment for opioid dependence can be effective.... Buprenorphine is an effective, safe medication for use in the treatment of opioid dependence and is a valuable addition to the formulary of medications for treating opioid dependence.

Buprenorphine is also reported to have lower overdose potential, although caution should still be exercised when prescribing to patients using other CNS depressants such as alcohol, benzodiazepines, barbiturates, neuroleptics and tricyclic anti-depressants.

Buprenorphine is a schedule 3 drug subject to special prescription requirements and must be kept in a CD cabinet, but there is no requirement to keep registers – although invoices must be retained for 2 years.

---

1 See RCGP (2004) ‘Guidance for the use of buprenorphine for the treatment of opioid dependence in Primary Care’, for further details. Copy to be found in references section of this guidance.
The Need for a Supervised Methadone and Buprenorphine Consumption Programme

The supervised consumption of opiate substitution treatments can:

- Prevent sale on the black market.
- Provide an opportunity for the pharmacist to build a rapport with the patient which is to the patient’s benefit and may well result in more orderly behaviour within the pharmacy.
- Provide an opportunity for the pharmacist to make a daily assessment of compliance with the programme and of the general health and well being of the patient and advise accordingly.

Whilst supervision is desirable when patients enter the programme, it should also be noted that supervision itself may create a secondary dependence. It is important that once the patient is stabilised that they are trusted to accept a degree of responsibility, by extending treatment to the introduction of ‘take home’ doses. For example, from daily to twice weekly down to once weekly.

**Methadone**

Although Methadone Mixture has a relatively low street value, there may be a temptation for the client to sell the daily dose to help pay for a more euphoric alternative. In most cases it is preferable that consumption of the daily dose of methadone is supervised by a pharmacist at the initiation into treatment. Through daily observation the pharmacist can monitor that adequate blood and tissue levels of methadone are maintained, therefore reducing the need for additional opiates.

Supervising the consumption of methadone to patients on a daily basis has emerged as a key component of methadone programmes. Supervised consumption is recommended by the Clinical Guidelines for a minimum of 3 months or until patient compliance with treatment is achieved. This has the additional benefit of reducing the overdose risk during induction into treatment and reducing the diversion of methadone which also contributes to drug related mortality among those not in treatment both nationally and locally.

Methadone has a narrow safety window and small amounts can be lethal for those not used to it, which makes diversion a particular concern. Moreover, tolerance can drop quickly such that missed doses resulting in reduced opiate tolerance increase the risk of accidental overdose.

**Buprenorphine**

Currently Buprenorphine is associated less with abuse although evidence suggests it is traded on the black market for oral consumption. However, in the late 1980s in Glasgow there was widespread abuse of Buprenorphine where, due to its ready solubility, it was prepared and injected. Similar health problems and injecting related complications have been found in France where monthly dispensing resulted in approximately a half of clients injecting their own buprenorphine. A study of treatment centres in France reported 52%
experiencing medical complications from injecting the drug with 33% experiencing hospitalisation as a result.\(^4\) Reports suggest buprenorphine injection is associated with acute hepatitis in patients with Hep C.\(^5\)

On the basis of the Scottish experience the clinical guidelines concluded that ‘safeguards such as daily dispensing, with supervised consumption, should be inherent to any well-delivered buprenorphine substitution programme’ (DoH, 2007)

There has recently been much debate regarding crushing buprenorphine tablets as part of supervised consumption programmes. Crushing buprenorphine tablets is not included in the product licence. However, doing so can significantly promote client compliance through on-premises consumption given the practical difficulties of effectively supervising consumption of whole tablets which can take 5-10 minutes to dissolve under the tongue and possibly longer depending on the dose. Ineffective supervised consumption is associated with the development of a market for partially consumed buprenorphine tablets, referred to as ‘fuzzies’ by users in some parts of the country.\(^6\) In Australia it is mandatory in certain states, including Victoria, to crush the buprenorphine tablets unless a prescriber specifically requires otherwise.\(^7\)

This debate has culminated in:

- The Royal Pharmaceutical Society of Great Britain (RPSGB) releasing guidance to members advising that crushing can take place where the pharmacist and client agree to this course of action, the pharmacist is confident that this is in the best interests of the client, and it does not compromise the efficacy of the treatment.
- The National Pharmaceutical Association (NPA) advising members that they will indemnify members crushing buprenorphine, against the licence, as long as they comply with a defined protocol for doing so. See appendix 2 for further details. Note: this covers NPA members only.

There are some key principles of the NPA and RPSGB guidance:

- **There must** be collaboration between pharmacist, prescriber and client to ensure that everyone understands:
  - the objectives behind a supervised scheme
  - the reasons for the crushing of buprenorphine,
  - that crushing is outwith the manufacturer’s marketing authorisation
  - there is clear understanding of the clinical and logistical implications of crushing.

- Pharmacies crushing buprenorphine need to be satisfied that crushing is in the patient’s best interest; crushing must be for the benefit of the patient rather than the convenience of the pharmacist. Pharmacies need to be satisfied that there is a true clinical need for crushing. They also need to consider the potential for distortion of the bioavailability profile of buprenorphine as a result of crushing.

Clinicians have sought to provide a supervised consumption protocol for crushed buprenorphine on the grounds that it increases the efficacy of treatment by significantly

---

\(^5\) Ibid.
\(^6\) Posting to SMMGP discussion group.
\(^7\) NPA Guidance ‘Supervised Subutex Supply – Professional Indemnity’ see appendix 2.
reducing opportunities for diversion and non-compliance with the treatment regime. This is especially important during induction into treatment and as an option available if there are concerns about compliance in later stages of treatment process.

With regard to bio-availability there are a number of precautions the pharmacist should take to ensure maximum bioavailability of buprenorphine when crushed:

- Bio-availability is seriously reduced if taken orally – studies suggest $\frac{1}{2}$ bioavailability of oral compared to sublingual consumption.\(^8\) Therefore even crushed it should be deposited under the tongue to dissolve. The manufacturers suggest that the active ingredients should be gone by 2-3 minutes.\(^9\)
- Some pharmacists are also concerned about reduced availability due to wastage in crushing. Even breaking the tablet along the score line will speed up dissolution and reduce value on the black market as the saliva will have begun to dissolve the matrix.\(^10\) In Australia advice is not to crush to a fine powder but to granules so that less of the medication clings to the crusher.\(^11\) Loss due to crushing appears to be highest with low dose pills and negligible with higher dose pills.\(^12\)
- A trial in Australia showed that crushing to granules led to no apparent change in bioavailability.\(^13\)

---

\(^8\) Jenkinson et al. (2005) 'Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?’, in *Addiction*, 100:197-205.

\(^9\) Posting to SMMGP discussion group 19/04/05

\(^10\) Posting to SMMGP discussion group 01/4/04 from Community Pharmacist.

\(^11\) Posting to SMMGP discussion group 01/4/04

\(^12\) Posting to SMMGP discussion group 02/04/04, Shared Care Substance Misuse Manager based on local London trial prior to commencement of crushing scheme.

\(^13\) Posting to SMMGP discussion group 12/3/04
Aims and objectives of the service

To ensure compliance with the agreed treatment plan by;
- Dispensing prescribed medication in specified instalments
- Ensuring each supervised dose is correctly administered to the patient for whom it was intended (doses may be dispensed for the patient to take away to cover days when the pharmacy is closed)
- Liaising with the prescriber, named key worker and others directly involved in the care of the patient (where the patient has given written permission)
- Monitoring the patient’s response to prescribed treatment; for example if there are signs of overdose, especially at times when doses are changed, during titration of doses, if the patient appears intoxicated or when the patient has missed doses and if necessary withholding treatment if this is in the interest of patient safety, liaising with the prescriber or named key worker as a appropriate
- Improving retention in drug treatment
- Improving drug treatment delivery and completion

To reduce the risk to local communities of:
- Overuse or underuse of medicines
- Diversion of prescribed medicines onto the illicit drugs market
- Accidental exposure to the dispensed medicines

Operational Procedures

Outlined below are the Operational Procedures for delivering substitution therapy with supervised consumption via pharmacies. All staff, including locums, should be aware of the following procedures. It is these procedures, along with the key principles outlined immediately above, which constitute a robust protocol. The operational procedures below make specific reference to buprenorphine, integrating all elements of the NPA model protocol.

Accepting new clients into Supervised Consumption

- The prescriber, usually GMW, Shared Care GP, or Lifeline or the key worker will ask the client which pharmacy participating in the supervised consumption programme, would be most convenient for daily visits and at what times.

- The prescriber will contact that pharmacist before issuing the first prescription to ensure the pharmacist has the capacity to accept the client at that time.

- The prescriber or keyworker will complete the Patient Identification Form with the client including signing the form and stamping it with an official clinic stamp. (see appendix 4)

- The prescriber should complete appendix 6 for all clients prescribed supervised buprenorphine
All prescriptions will have the agreed dispensing pharmacist name printed on the prescription
- The client will attend the named pharmacy with their prescription for supervised methadone or buprenorphine consumption as agreed with the prescriber or keyworker. The Patient Identification and Record Form must accompany the prescription.

- Clients will be briefed by the prescriber on the date of commencement of supervised consumption. The prescriber should inform the client fully of what is expected when commencing supervised consumption. In doing so the prescriber will inform the client that the pharmacy will enter into a contractual arrangement with the client which the client will be expected to adhere to.

- For clients in receipt of crushed buprenorphine a signed agreement should be sought from both the prescriber and client as confirmation that they understand the implications associated with supervised supply of crushed buprenorphine and that they agree to participation on this basis. See appendix 2 for the model supplied by the NPA.

Client/pharmacy agreement (contract)

- Clients must have a written contract with the drug service, part of which covers behaviour in the pharmacy. However, it is important that pharmacists use the contract (Appendix 5), outlining in greater detail the procedure for daily supervision.

- The aim of the contract is to reduce the potential of misunderstandings and bad feeling to arise between client and pharmacist.

Clients should be informed in advance of what arrangements you make for when the pharmacy is closed.

In addition the client should be given a practice leaflet detailing additional professional services offered by the pharmacy. Health promotion is an important issue for this group of patients and pharmacists should take every opportunity to provide advice on diet, exercise and oral hygiene.

Identification of clients

- The clients' identity must be checked to ensure the prescription is dispensed to the correct person.
- The Patient Identification Form (appendix 4) aims to assist this process.
- If there is any uncertainty with the identity of the client the prescriber must be contacted and the dose withheld until the individuals identity is ascertained.

Controlled drugs prescriptions

Controlled Drug prescriptions are subject to additional regulation and therefore must be checked before medication is dispensed.

- The prescription must be checked for legality
  Statutory instrument No2005/2864 has amended the Misuse of Drugs Regulations 2001 to allow all details, including the date, to be computer generated. This removes the
need for doctors to apply for handwriting exemptions to computer generate prescriptions. However, the **signature must be handwritten**.

- Methadone should be prescribed on FP10(MDA) for no more than 14 days.
- If more than one item is prescribed separate forms should be used as FP10(MDA) only has space to record 14 dispensing episodes.
- Where the total daily dose of buprenorphine prescribed requires the dispensing of two tablets i.e. 8mg and 2mg for a 10mg total daily dose, only one supervision fee may be claimed as this is not classed as two supervisions. The intention of the supervision fee is to cover supervision of one dose regardless of the number of tablets required to make up that dose.
- Buprenorphine may be prescribed on FP10(MDA) or FP10HP(AD).
- If the starting date for dispensing is other than the date of writing the prescription, this must be clearly stated. Start dates should always be clear to prevent the possibility of obtaining two doses at the end of one prescription and the beginning of another.
- The prescription should provide clear dispensing instructions. The amount of the instalments and the intervals to be observed must be specified. Prescriptions ordering ‘repeats’ on the same form are not permitted.
- The prescription must specify clearly that supervision is required.
- The prescription should also state if the buprenorphine tablets are to be crushed.
- The prescription should not be in any way tampered with, or in a condition where the instructions are no longer clear – e.g. water damaged, torn etc.

Whilst the Home Office have confirmed that prescriptions can now be worded as follows ‘Instalment prescriptions covering more than one day should be collected on the specified day; if this collection is missed the remainder of the instalment (i.e., the instalment less the amount prescribed for the day(s) missed) may be supplied’, this provision should be used in exceptional cases only, and the prescriber must alert the pharmacist that this instruction is to be made. The pharmacist should also notify the prescriber when this occurs.

**Emergency supply** of methadone mixture and buprenorphine – The Misuse of Drugs Act does not allow for the ‘emergency supply’ of Schedule 2 or 3 Controlled Drugs (exemption – phenobarbitone or phenobarbitone sodium for epilepsy). Doses should never be given in advance of receipt of a valid prescription at the pharmacy. Phoned or faxed prescriptions for controlled drugs are also illegal.

Pharmacists must satisfy themselves of the legality of the prescription, and its clinical appropriateness. If you have any doubts about the validity of the prescription – contact the prescriber.

If a client’s prescriber changes, the clinic or service should inform the pharmacist of this change.

---

**Preparation of medication**

- Methadone - The daily amount should be measured into a suitable container, capped and labelled. When the client arrives, ideally the measured dose may be poured into a disposable cup. Please note drinking medicines directly from the bottle can set a bad example to children in the pharmacy.

- Buprenorphine – The prescribed tablets should be removed from the foil and placed in an appropriate container. If they are to be crushed they should be crushed into granules rather than a fine powder, in the client’s presence. This way the client can confirm their dose before the medication is crushed. An appropriate crushing device should be used that minimises any loss of dose and has the confidence of clients.

Sugar free or colourless methadone mixture should only be dispensed if specifically requested on the prescription.

It is important that the dose is ready for the client’s arrival. The whole operation should be as discreet and efficient as possible, maintaining the patient’s dignity and saving the pharmacist’s time.

Doses that are collected to be taken on Sundays or bank holidays must be dispensed in a container with a child resistant closure. Clients must also be advised to store their medication out of the reach of children.

**Discreet and efficient supervision by Pharmacist**

Consumption should take place in discreet area, or at times when the pharmacy is not likely to be busy, as agreed with the pharmacist. This will be discussed with pharmacies as part of the application process.

- Methadone - The pharmacist must be satisfied that the dose has actually been swallowed, for example, by water being swallowed after the dose or conversing with the client to ensure that the methadone is not retained in the mouth. ‘Spit Methadone’ has a street value and some clients may be under a great deal of pressure to hand over their dose to others.

- Buprenorphine – the tablet or crushed granules must be tipped directly under the tongue without handling and the client supervised until the tablets have dissolved – this can take 3-7 minutes depending on the dose, the client and whether the tablets have been crushed. Providing or advising the client to bring a drink of water with them for consumption before administering their medication, will help speed up the process. Clients should be advised that increased or excessive saliva production may reduce the effectiveness of the drug and is not desirable, and that saliva should be kept in the mouth rather than swallowed during dissolution. You may also wish to inform them that the medication has a bitter taste.
Disposal of waste

Labels should be removed from containers and the container rinsed and immediately discarded.

Waste should be disposed of safely and steps taken to minimise risks of infection through meticulous hygiene and vaccination of staff if required.

Maintenance of patient records

Two forms are required to be completed for supervised consumption:

- Patient Record Form – Pharmacists are responsible for maintenance of each client’s Patient Medication Record. You should be able to record daily attendance, missed doses and other concerns that you may need to report back to the prescriber. (See appendix 7). The client’s details should be filled in at the top of the form and a tick should be placed against the relevant date box for every day on which medication is issued to this client.

- Blackburn with Darwen Borough Council or BwD CCG at any time may request to see patient record forms for the purposes of audit in line with the increased requirement for commissioners and CCGs to monitor the use of controlled drugs in their areas. If you have an alternative patient record system, this can be used as long as it allows you to record daily attendance, missed doses and other concerns that you may need to report back to the prescriber. The notes section of the form allows you to note any concerns or action regarding a particular client. Thus the Patient Record should note any additional services (e.g. general medical information) or advice provided to clients, referrals made on their behalf and liaison with the prescriber. Any alternative or electronic system must also be amenable to audit.

- If buprenorphine tablets have been crushed, this must be indicated on the Patient record.

- Record of Medication Administered – this allows you to record the total number of daily supervised consumptions conducted and is purely for remuneration purposes. See appendix 8 for this pro forma and guidance regarding completion and submission.

- The Controlled Drugs Register must also be completed for methadone and invoices, requisitions and orders for Buprenorphine must be kept for 2 years.
  Subsequent to statutory Instrument 2005/2864 a controlled drugs register may be computerised and copies of this register may be requested by the Secretary of State or an authorised person.
  Requisitions and orders for buprenorphine may be preserved in original form or as a copy on computer.15

Concerns regarding presenting clients

You must contact the prescriber/keyworker in the following circumstances:

- The patient does not consume the whole dose under supervision
- The patient appears to be ill

15 See new regulation 24a which has been added to the 2001 regulations.
• The patient tries to avoid supervision or the process for proper consumption

• The patient appears to be intoxicated - Clients stabilised on methadone or buprenorphine should be clear-headed and coherent. If the pharmacist considers the client is grossly intoxicated, the prescriber should be contacted and the dose withheld.

Methadone taken on top of other opiates, alcohol or benzodiazepines may increase the sedative effects leading to respiratory depression and potential overdose.

Buprenorphine is a partial opiate antagonist and, in isolation is less likely to cause overdose in opiate naive individuals, although it is still a risk. The risk with buprenorphine is also increased when taken in combination with alcohol and benzodiazepines.

**Missed doses may result in a drop in opiate tolerance with an increased risk of accidental overdose.**

• The patient misses doses - If a client comes in after having missed three consecutive doses, their dose should be withheld and they should be referred back to the prescriber. If clients regularly miss a single day's dose, for example 3 doses in a 7-day period, the prescribing doctor should be informed and sent a copy of the patient medication record showing the pattern of missed doses.

Missed doses should not be replaced or issued at a later date.

• There are problems with the prescription – e.g. uncertainty about dates, validity, has been tampered with etc.

• The behaviour of the client is unacceptable and contrary to the client/pharmacy agreement - ultimately only you can decide what behaviour is 'unacceptable'. In circumstances where a dose is not administered, or you wish to cease future consumptions, both the client and prescriber must be made aware of this decision.

Appendix 9 further outlines circumstances in which the pharmacist should contact the prescriber. The decision is a professional one that should be made after considering the risk to the patient of non-disclosure and the damage that may be done to the supportive relationship between the pharmacist and the patient. Patient confidentiality should be respected at all times.

Contact with the prescriber should be swift following any reason for concern and especially where does are missed or further consumption has been withdrawn. Appendix 10 provides a proforma which can be completed and faxed, or completed and the details telephoned through to the prescribing agency. A copy of the original should be kept with the patient record for audit purposes. It is important that this information is relayed to the appropriate prescriber or keyworker for a client.

As an independent service provider commissioned by Blackburn with Darwen Borough Council (Public Health) it is a requirement to report any incidents to Lancashire Commissioning Support Unit who act on behalf of Blackburn with Darwen Borough Council as well as the Council as detailed in the Public Health Contract terms and conditions.

Please also report any controlled drugs issues to the NHS England Local Area Team (LAT)

**Judith Johnston, Quality and Safety Manager**
Pharmacist Training & Qualifications

Pharmacists involved in the provision of this service must have completed or plan to complete within 6 months of joining the scheme:


A copy of the record of assessment must be sent to the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council.

If a pharmacist signs up not having completed the open learning programme and e-Assessment, they must successfully complete them within 6 months of their being accepted on to the programme. The named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council must be informed once complete and a copy of the record of assessment sent to the address indicated on the “Application to Join the Pharmacist Supervised Consumption Scheme” form in Appendix 3.

Pharmacists participating in the service must:-

- Ensure compliance with all legal and professional requirements.

- Ensure they have appropriate insurance cover – the CPPE course outlines how you can check this.

- From Jan 1st 2005 the pharmacy must have a Standard Operating Procedure (SOP) for all personnel operating the scheme. SOPs are intended to support pharmacists working in the community by setting out strategies for risk management and harm reduction that comply with clinical governance requirements. The NPA provides guidance for developing Standard Operational Procedures for dispensing schedule 2 and 3 controlled drugs (see www.npa.co.uk).

- Supervise the daily consumption of methadone mixture (1 mg per ml) or buprenorphine 0.4mg, 2mg or 8mg sublingual tablets in accordance with the prescriber’s wishes;

- Follow the procedures recommended in local guidelines.

- Respect patient confidentiality at all times.
Ensure an accredited pharmacist, as outlined in the training and qualifications section, provides this service at all times.

Inform the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council if there is an interruption to the delivery of this service by an accredited pharmacist. See appendix 11 ‘Changes in the provision of Supervised Consumption of Methadone or Buprenorphine by Accredited Pharmacist’.

Ensure new staff or locums are fully aware of the SOP and are able to enact this agreement appropriately. Locums should undergo accredited training.

Allow regular audit of service provision and patient records in line with Blackburn with Darwen Borough Council requirements and those to be developed by a Controlled Drugs Inspectorate and the Healthcare Commission.

Report any incidents to the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council.

**Liaison**

Pharmacists must develop and maintain close links with prescribers and drugs services.

The pharmacist may be contacted by the prescriber/ keyworker:

- For feedback after the first week of treatment
- After three months to feed into the review of the care plan/treatment package
- As required, to update on treatment goals or any significant issues regarding the management of the clients treatment package.

At all other times all steps should be taken to maintain the client’s confidentiality, with all staff protecting the privileged information they are party to by not divulging anything about the clients outside of the pharmacy.

Daily contact with the client may allow the pharmacist to provide health promotion support and monitor patient compliance, suspected alcohol/drug intake, physical appearance and family support. People who are dependent on substances often have difficulty in accessing help and other social care.

As you get to know the patient you may be in a position to notice deterioration in their health.

The Substance Misuse in General Practice website is also a useful source of information and guidance and contains discussion groups to support those working with substance users. This can be found at www.smmgp.co.uk

**Premises**

Pharmacies which offer the Supervised Methadone and Buprenorphine Consumption Service shall have the following facilities:

- A patient medication record
• Appropriate storage conditions for the increased supply of methadone/buprenorphine.

• Unless specifically exempted by Blackburn with Darwen Borough Council, the service must be provided in pharmacy premises that meet the national standard for consultation areas i.e.

1. The consultation area should be a designated area were both the patient and pharmacist can sit down together
2. The patient and pharmacist should be able to talk at normal speaking volumes without being overheard by other visitors to the pharmacy, or by staff undertaking their normal duties
3. The consultation area should be clearly designated as an area for confidential consultations, distinct from the general public areas of the pharmacy.

• an area for display of relevant health promotion leaflets including advice on the safe and secure storage of medicines.

Payments

Payments will be made per supervision at a rate of:

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>£1.75 per dose supervised</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>£2.50 per dose supervised</td>
</tr>
</tbody>
</table>

Please note:

➢ Where the total daily dose of buprenorphine prescribed requires the dispensing of two tablets i.e. 8mg and 2mg for a 10mg total daily dose, only one supervision fee may be claimed as this is not classed as two supervisions. The intention of the supervision fee is to cover supervision of one dose regardless of the number of tablets required to make up that dose.

➢ Supervision on Sundays is not routinely requested by the Substance Misuse Service. If Sunday supervision is necessary, the prescription will be clearly marked. If a pharmacy is open on Sundays and chooses to supervise the consumption of medicines, or a client requests supervision on a Sunday, a supervision fee must not be claimed if it is not requested on the prescription.

➢ Morning and afternoon supervision is not routinely requested by the Substance Misuse Service. If morning and afternoon supervision is necessary, again the prescription will be clearly marked. If a client requests morning and afternoon supervision the pharmacist should ask the client to discuss the matter with their prescriber. If morning and afternoon supervision is not requested on the prescription, only one supervision fee can be claimed.

Pharmacists will not be limited to numbers of clients that they ‘take on’ at any one time as long as they can fulfil their obligations to providing a full and high quality service to clients.

Payments will be made monthly following the submission of the Record of Medication Administered form (see appendix 9)
These forms should be sent to the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council by the 7th of the following month to be paid at the end of the month. Payments against late forms will be held over until the end of the following month.

Payments can only be made to pharmacies who have signed up to this scheme and have agreed to provide the service outlined above. Payments are Pharmacy not pharmacist based.

**Leaving the scheme**

If pharmacists wish to leave the scheme at any point they should inform the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council of this intention, three months in advance. This will enable prescribers to make alternative arrangements allocating clients to alternative scheme providers.
Appendices

These appendices provide further information and are for reference and illustrative use only.

Blank copies of all forms in these appendices are found in the resources section.

Acknowledgements

Teresa Rutter, Drug Related Death Researcher, Commissioning & Modernisation Blackpool PCT whose original guidance this document was based on.

Andrea Loudon, Head of Pharmacy and Medicines Management, Cumbria PCT for permission to use their Supervised Consumption of Methadone and Buprenorphine – Guidelines for Pharmacists
Appendix 1 – Models of Care Pathway

Pathway

Pharmacy Pathway for the Observed Consumption of Methadone and Consumption of Buprenorphine

Aim

This is the pathway for clients who, in line with the guidelines on good clinical practice, require observed consumption of Methadone or Buprenorphine.

Who is this pathway for?

- Clients who are already receiving treatment, that includes prescribed drugs, from one of the services in East Lancs and Blackburn with Darwen.
- Clients who have a care plan in place

Who is the pathway not suitable for?

- Clients who have not yet been fully assessed.
Pharmacy Pathway for the Observed Consumption of Methadone and Consumption of Buprenorphine

1. Telephone call by service provider to pharmacy to request supervision for new client.
   - Name of client and details of prescription provided.
   - Service provider to check prescription is legal & correct

2. Code of conduct explained to client by service provider and signed by client

3. Client presents at pharmacy with prescription written by service provider. Identity of client confirmed

4. Pharmacist checks prescription details are correct and legal

**FIRST VISIT**

- Pharmacist explains guidelines to client and introduces them to key members of staff
- Negotiates suitable time for collection of dose
- Prescription prepared

**REPEAT VISIT**

- Prescription prepared in advance

**Regular attendance**

- Assessment of client’s health and well-being
  - Acute /other Health Issues
  - No Health Issues
  - Intoxicated
  - Client asked to come back later in day. Record action on client record sheet
  - Supervised consumption

**Irregular attendance**

- Client fails to attend for three consecutive doses, further supply withheld.
  - Contact service provider
  - Supply withheld Contact service provider

Ref: protocols on identification of clients

See Needle Exchange Pathway

Health Promotion

Information and advice provided, with reference to other health professionals e.g. Dentist Refer as appropriate

Client requiring supervised consumption as part of treatment package

FIRST VISIT

REPEAT VISIT

Regular attendance

Irregular attendance
Appendix 2 - RPS Press release and NPA model protocol

Royal Pharmaceutical Society
1 Lambeth High Street, London SE1 7JN
Tel: 020 7572 2335
Fax: 020 7572 2503

News release

For immediate release
Tuesday 29 March 2005

SOCIETY GUIDANCE FOR BUPRENORPHINE TABLETS

The Royal Pharmaceutical Society of Great Britain is issuing guidance to pharmacists regarding the crushing of buprenorphine sublingual tablets (Subutex) prior to consumption. Crushing buprenorphine sublingual is outside of the manufacturer’s marketing authorisation and will render the product unlicensed.

Pharmacists who are considering crushing buprenorphine tablets prior to consumption need to be satisfied that this is in the patient’s best interests as there is the potential for the product’s bioavailability profile to be distorted. The prescriber and the patient should agree to the tablets being crushed prior to consumption – and the patient should be informed of the risks and the benefits of crushing. Any crushing of buprenorphine tablets should be for the benefit of the patient, rather than the convenience of the pharmacist.

A pharmacist may assume some liability for the supply of a product outside licensed indications and should ensure that their indemnity insurance covers such activity.

In support of this guidance, the National Pharmaceutical Association (NPA) is offering the following advice its members:

The NPA will indemnify NPA members involved in the provision of a crushed Subutex service, provided they comply with a defined protocol. Further details of this protocol can be found at the CDA channel on NPAnet, the Association’s member-only intranet.

Ends

For further information please contact Natalie Sticklen or Felicity Slayford in the Royal Pharmaceutical Society of Great Britain’s Public Relations Unit
020 7572 2335/6
SUPERVISED SUBUTEX SUPPLY – PROFESSIONAL INDEMNITY

Background

Subutex (buprenorphine) is used as an adjunct in the treatment of opiate dependence. Subutex is a sublingual formulation and it is not uncommon for addicts, even where their consumption is being supervised, to remove the tablet and then sell this on the black market or inject it.

As a result, it is now common place for addiction centres to request that the tablets are crushed prior to consumption for those addicts where diversion is suspected or where a high dose means an unacceptably long waiting time for tablets to dissolve. The instances of crushing are on the increase. In Australia it is mandatory in certain states to crush the tablets unless a prescriber specifically requires otherwise.

Crushing Subutex is outwith the manufacturer’s marketing authorisation and so the manufacturer is unwilling to recommend or endorse the crushing of tablets. Their view is that no studies have been carried out on the impact of crushing the tablets. Crushing increases the surface area of the drug and will thus increase the dissolution and absorption of the drug. On the other hand, crushing increases saliva production which will enhance the possibility of swallowing unabsorbed drug therefore reducing slightly its blockade effects.

Professional Indemnity

The NPA will indemnify NPA members involved in the provision of a crushed Subutex service. However this cover is conditional upon participating members complying with the "model protocol" set out below.
Supervised Consumption of buprenorphine – Model protocol

The following requirements are over and above the general legal and ethical requirements associated with the running of a pharmacy business and the specific requirements relating to the provision of controlled drugs and services to drug misusers.

- Pharmacies crushing buprenorphine need to be satisfied that crushing is in the patient’s best interest; crushing must be for the benefit of the patient rather than the convenience of the pharmacist. Pharmacies need to be satisfied that there is a true clinical need for crushing. They also need to consider the potential for distortion of the bioavailability profile of buprenorphine as a result of crushing.

- Pharmacies must have a standard operating procedure to cover all the processes involved in the scheme which is readily available to and understood by all staff (and locum pharmacists) involved with the scheme.

- There must be collaboration between pharmacist, prescriber and client to ensure that:
  - everyone understands the objectives behind a supervised scheme
  - the reasons for the crushing of buprenorphine,
  - that crushing is outwith the manufacturer’s marketing authorisation
  - there is clear understanding of the clinical and logistical implications of crushing.

- A signed agreement should be sought from both the prescriber and client as confirmation that they understand the implications associated with supervised supply of crushed buprenorphine and that they agree to participation on this basis.

  A model patient information/consent form is included as an Annex.

- Prescriptions must clearly indicate that the consumption is to be supervised. Ideally the prescription should also state that the buprenorphine tablets are to be crushed. Alternatively a signed agreement between the prescriber and pharmacist could specify circumstances in which it is appropriate to crush tablets – for example where diversion is suspected, where prescribed doses exceed 8mg or for all clients.

- Pharmacists must satisfy themselves of the legality of the prescription, and its clinical appropriateness.

- Pharmacists should refuse to supply, and contact the prescriber if:
  - There are any queries with the prescription
  - There is any uncertainty with the identity of the client
  - The client misses the number doses prescribed in local treatment agreements
  - The client avoids, or attempts to avoid, supervision
  - The client does not consume the full dose, or attempts to avoid the process for proper consumption
  - The patient appears to be ill, under the influence of alcohol or other drugs to the extent that in the pharmacist’s judgement this may impair treatment
  - The client displays threatening, violent or abusive behaviour toward staff

- Pharmacists must keep adequate records of supply preferably on the PMR clearly indicating that a crushed supply has been made.
Appendix 3 - Application to Join the Pharmacist Supervised Consumption Scheme

AGREEMENT

I apply to be paid for pharmacist supervision for methadone and buprenorphine consumption by drug misusers in the premises named below in line with the Service Specification and to submit a monthly log of activity to the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council.

The owner/manager is an NPA member: -

................................................................. NPA member? Yes □ No □

The pharmacy is open for ( 5 ) ( 6 ) ( 7 ) days a week. (Circle correct figure)

I will claim the fees appropriate to this number of days opening following supervision of methadone and buprenorphine consumption.

Signed: ........................................................................................ Contractor

Pharmacy Name: ........................................................................................

Pharmacy Address: ..................................................................................

.............................................................................………

Tel No: ..............................................................................................

Date: .................................................................................................

Please provide details of those Pharmacist(s) that will be providing the Supervised Consumption Service. Copies of CPPE certificates should be sent to the contact address below.

<table>
<thead>
<tr>
<th>Name(s) of Pharmacist(s)</th>
<th>CPPE “Substance Use and Misuse” Pack already completed (Please tick)</th>
<th>CPPE Pack to be completed within 6 months (Please tick)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pharmacies wishing to join the scheme should complete this form and return it to:
# Appendix 4 - Patient Identification Form

## Client Information

<table>
<thead>
<tr>
<th>Client Name:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DoB:</td>
<td>_______ Gender:</td>
<td></td>
</tr>
<tr>
<td>Signed:</td>
<td></td>
<td>Date:</td>
</tr>
<tr>
<td>Client</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Medical Service Details

<table>
<thead>
<tr>
<th>Doctor:</th>
<th>Keyworker:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic address:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telephone:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinic Stamp**

<table>
<thead>
<tr>
<th>Signed:</th>
<th>Doctor/Keyworker</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## For the Pharmacist

The client should present a form of ID which contains either a photograph and name or name and address which match that given above.

Acceptable forms of ID include:
- Photo ID
- Diving licence, passport, proof of age card e.g. prove it, photo student ID,
- Name and address ID – no older than 3 months
- Bank statement, credit card statement, utility bill (not mobile phone bill), benefits correspondence, Council tax bill or payment book.

<table>
<thead>
<tr>
<th>Form of ID Shown:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date:</td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX 5

Client/Pharmacy Agreement

We are pleased to welcome you to the East Lancs & BwD Supervised Consumption Scheme and wish you all the best with your treatment. We aim to offer you a discreet and efficient service that supports you in achieving your treatment goals.

This ‘agreement’ sets out the arrangements for the service and a brief explanation as to why these arrangements are necessary. The pharmacist will go through each of the points with you and explain any that you are unsure about.

When you have completed the Agreement, the pharmacist will introduce you to the staff so that they know who you are and can help you should you require it.

We hope that the scheme proves helpful to you.

<table>
<thead>
<tr>
<th>The Arrangements</th>
<th>Why they are necessary</th>
</tr>
</thead>
<tbody>
<tr>
<td>We are available to supply your medication between: From…………To……………..</td>
<td>We want to give you your medicine as quickly as possible. We prepare your medicine first thing in the morning and write up our records before the shop closes.</td>
</tr>
<tr>
<td>We will need some way of identifying you. Our pharmacist will explain how this is done.</td>
<td>We want to ensure that we don’t give your supply to anyone else</td>
</tr>
<tr>
<td>You will need to collect your take home doses on………………………..………. for weekends and Bank Holidays</td>
<td>The pharmacy is closed on ……………day and ………..day and on Bank Holidays. Opening times are:</td>
</tr>
<tr>
<td>If you have missed three days collections in a row, we cannot supply your medication without speaking to your prescriber..</td>
<td>Your tolerance to the drug quickly drops and to take the full dose may risk your health</td>
</tr>
<tr>
<td>We must supervise you taking your medicine because this has been stipulated on your prescription</td>
<td>This is done to support you achieving your treatment goals and to reduce the risk of overdose</td>
</tr>
<tr>
<td>When you collect your medication we need time to update our records. Please be patient</td>
<td>By law, we have to make detailed records on each collection. We cannot do this in advance.</td>
</tr>
<tr>
<td>If you lose your prescription, we cannot supply the medication to you no matter how well we know you</td>
<td>Again, by law, we can only supply medications with a legally written prescription. If you have lost one you will need to contact your prescriber.</td>
</tr>
<tr>
<td>We cannot give you ‘missed doses’ that you have not picked up</td>
<td>The supply of your medication has to be made on the day and date specified on the prescription.</td>
</tr>
<tr>
<td>Please bring your new prescription promptly before, or just after your current one finishes</td>
<td>There is sometimes a waiting list for places. If you do not show we may have to give your slot to someone else</td>
</tr>
</tbody>
</table>
We would like you to come alone and to behave in a reasonable manner in the pharmacy and in the area outside the pharmacy.

<table>
<thead>
<tr>
<th>Please feel free to ask about other health related issues that maybe worrying you.</th>
</tr>
</thead>
<tbody>
<tr>
<td>We offer information and advice on health related matters to all members of our communities. You are a customer of ours and we value your custom.</td>
</tr>
</tbody>
</table>

**Confidentiality:** We respect your right to keep matters relating to your health private and confidential and shall endeavour to provide a confidential service for you. However we may talk to your GP/Prescriber or drug therapist about your health care or medicines.

<table>
<thead>
<tr>
<th>Name of Pharmacist:</th>
<th>Pharmacy Stamp:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phone number of Pharmacy:</td>
<td></td>
</tr>
<tr>
<td>Name and contact details of GP/Prescriber:</td>
<td></td>
</tr>
<tr>
<td>Name and contact details of therapist:</td>
<td></td>
</tr>
<tr>
<td>Patients signature:</td>
<td>Date:</td>
</tr>
<tr>
<td>Print Name:</td>
<td></td>
</tr>
<tr>
<td>Pharmacists signature:</td>
<td>Date:</td>
</tr>
</tbody>
</table>

**Complaints procedure**

If you are not satisfied with the service that you have received, please speak with your pharmacist, therapist or drugs worker.

Your complaint will be investigated and you will be kept informed of the process and the outcome. A complaints procedure will be made available to you on request.

**Notes or Comments**

We value your custom and will endeavour to do all we can to meet your health needs.
Appendix 6 - Client leaflet – Buprenorphine

Client Leaflet
Supervised Buprenorphine

Your doctor has prescribed buprenorphine and stated that this is to be “supervised consumption”. This means the following must happen.

- You remove any chewing gum or sweets from your mouth and dispose of them in a waste bin.
- You come into the pharmacy on your own.
- You hand in your medication card
- We positively identify you
- You will be provided with a drink of water as this speeds up the time it takes for the tablets to dissolve.
- The dispensed tablet is taken from the container with your name on and squeezed out of the foil and into a plastic medicine measure
- If the prescriber specifies “crushed” then the tablet(s) will be broken into smaller granular pieces. This will have been explained to you by your prescriber as crushing is off-licence
- You are expected to tip the tablet(s) or granules under your tongue without touching them and hand back the measure.
- You must then sit down and allow these to dissolve - this usually takes between 3 and 5 minutes for tablets - significantly less time for granules.
- Once the tablets have dissolved you should report to the pharmacist and will be provided with a drink of water, which you should drink.
- You will then be given back your medication card and may leave.

Important
- Failure to follow the points above will result in the prescription being suspended and you being referred back to your doctor.
- Missing 3 consecutive doses will also mean that you have to contact your clinic/doctor.

Name of GP/ Prescriber: (please print)……………………………………

Prescriber’s signature:………………………………………………….. Date:………………

Clients Name: (please print)………………………………………………

Clients signature:………………………………………………………….. Date……………………..
# Appendix 7 - Record of Treatment

<table>
<thead>
<tr>
<th>Day</th>
<th>Dose taken</th>
<th>Dose Missed</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 8 - Pharmacy Claim Form

Application for payment in respect of Supervised Methadone and Buprenorphine Consumption

Claim for the Month of ______________________

Payment will be based on the total number of monthly supervised doses

I declare that for the above month:-

a) The doses were supervised as listed below and marked M or B (Methadone/ Buprenorphine)
b) There is a written procedure for locums on supervision arrangements
c) The service complies with the scheme Service Specification

| Client Initials | DOB | M/B* | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | Total |

*Please place an ‘M’ to indicate methadone or ‘B’ to indicate Buprenorphine.
Failure to distinguish between the two may result in all payments being made at the lower methadone rate.
Below each numbered column please place a tick (\(\checkmark\)) to indicate supervision or a cross (\(\times\)) to indicate no supervision has taken place.
Name of Pharmacist providing Supervised Consumption Service ............................................................

Signed ..................................................... Date .............................
Appendix 9 - When to Contact the Prescriber

CONSIDER CONTACTING THE PRESCRIBER IF:

- The patient appears to be ill
- The patient misses three doses
- The patient appears to be intoxicated e.g. alcohol, other prescription and/or illicit drugs
- The behaviour of the patient is unacceptable e.g. shoplifting, verbal and/or physical abuse
- There are problems concerning the prescription e.g. patient moves prescription, ambiguity of dates for dispensing, identity of patient in doubt
- The Pharmacist is aware of other issues that may affect treatment compliance e.g. being made homeless.

- The patient does not consume the whole dose under supervision
- The patient tries to avoid supervision
- The Pharmacist is contacted by secondary care Re: dosage information due to hospitalisation
- The client repeatedly misses odd days
- The Pharmacist believes there may be a concordance/drug interaction issue with other prescribed drugs being taken
- The client requests treatment that the prescriber can refer to/provide, e.g. Hep B Vac

Remember
- Missing doses may result in a drop in opiate tolerance with an increased risk of accidental overdose
- Clients stabilised on methadone or buprenorphine should be alert and coherent
- As you get to know the patient you may be in a position to notice deterioration in their health
- Only you can decide what behaviour is ‘unacceptable’.

Boxes with purple text require swift action
Issues in boxes with grey text should be dealt with at your own discretion
Appendix 10 - Pharmacist - Prescriber Contact Form

Client: __________________________

Doctor: __________________________

Keyworker: __________________________

Supervised consumption of prescribed medications has been withdrawn because the client above has:

☐ Missed three doses
  (please append a copy of the patient record form)

☐ Exhibited unacceptable behaviour
  Including: __________________________

☐ Refused to consume the whole dose under supervision

☐ Tried to avoid supervision

☐ Appeared intoxicated when attending the pharmacy
  Please give details: __________________________

☐ Been admitted to hospital

Further information


Signature of Pharmacist: __________________________

Date: __________________________

Please note this form is only for use when treatment is withdrawn – refer to the ‘when to contact the prescriber’ flowchart in appendix 8 for guidance where swift action is required.

The prescriber should deal with further issues at their own discretion and in discussion with clients.

Concordance/Drug interaction issues should similarly be dealt with at the discretion of the pharmacist and may require more urgency depending on individual circumstances.
Appendix 11 - Changes in the provision of Supervised Consumption of Methadone or Buprenorphine by Accredited Pharmacists

Pharmacy name: ________________________________
Pharmacy address: ________________________________
__________________________________________________

Please complete the relevant section:

Section A – newly qualifying pharmacists

________________________ has now _________ completed ________________________________
(Pharmacists name) (date) (Course name and provider)

__________________________________________________

Section B – change in accredited pharmacist

The Supervised Consumption of Methadone and Buprenorphine Scheme at ____________
will henceforth _________ be administered by ________________
(Pharmacy name) (date) (name)

who has completed __________________________________
(Course name, provider and date of completion)

Section C – Temporary / Interim arrangements

Between _________ and _________ the Supervised Consumption of Methadone and
Buprenorphine Scheme will be provided by ________________________.

This pharmacist has/has not completed an accredited course. (delete as appropriate)

Complete if appropriate __________________________________
(Course name, provider and date of completion)

__________________________________________________

This pharmacist must be aware of the Standard Operating Procedures for the scheme.

Section D – to be completed for any other changes to the scheme.

Please explain any other changes to the implementation of the scheme by trained pharmacists.

____________________________________________________________________________________

Please send to: the named contact advised by Lancashire Commissioning Support Unit (CSU) who
are acting on behalf of Blackburn with Darwen Borough Council
Resources

This section of this guidance document contains blank photocopyable forms required for the consumption of the Supervised Consumption of Methadone and Buprenorphine scheme, including:

- Application to join the scheme
- Patient Identification and Record of Treatment Form
- Pharmacist - Prescriber Contact Form
- Pharmacy Claim Form
- Notification of changes in the delivery of the scheme form
Application to Join the Pharmacist Supervised Consumption Scheme

AGREEMENT

I apply to be paid for pharmacist supervision for methadone and buprenorphine consumption by drug misusers in the premises named below in line with the Service Specification and to submit a monthly log of activity to the named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council.

The owner/manager is an NPA member: -

................................................................. NPA member? Yes ☐ No ☐

The pharmacy is open for (5) (6) (7) days a week. (Circle correct figure)

I will claim the fees appropriate to this number of days opening following supervision of methadone and buprenorphine consumption.

Signed: ............................................................................................................. Contractor

Pharmacy Name: ..................................................................................................

Pharmacy Address: .............................................................................................

...........................................................................................................................

Tel No: .................................................................................................

Date: ..............................................................................................................

Please provide details of those Pharmacist(s) that will be providing the Supervised Consumption Service. Copies of CPPE certificates should be sent to the contact address below.

<table>
<thead>
<tr>
<th>Name(s) of Pharmacist(s)</th>
<th>CPPE “Substance Use and Misuse” Pack already completed (Please tick)</th>
<th>CPPE Pack to be completed within 6 months (Please tick)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Pharmacies wishing to join the scheme should complete this form and return it to:
The named contact advised by Lancashire Commissioning Support Unit (CSU) who are acting on behalf of Blackburn with Darwen Borough Council.
Patient Identification Form

Client Information
Client Name: ____________________________________________
Address: ________________________________________________
DoB: ___________________ Gender: _________________________
Signed: ___________________ Date: _________________________

Medical Service Details
Doctor: ________________ Keyworker: ________________
Clinic address: __________________________________________
Telephone: ______________________________________________

Signed: ___________________ Doctor/Keyworker

Clinic Stamp

Date: ___________________

For the Pharmacist

The client should present a form of ID which contains either a photograph and name or name and address which match that given above.

Acceptable forms of ID include:
• Photo ID
• Diving licence, passport, proof of age card e.g. prove it, photo student ID,
• Name and address ID – no older than 3 months
• Bank statement, credit card statement, utility bill (not mobile phone bill), benefits correspondence, Council tax bill or payment book.

Form of ID Shown: ____________________________________________

Date: ________________
Pharmacist - Prescriber Contact Form

Client: __________________________

Doctor: __________________________

Keyworker: __________________________

Supervised consumption of prescribed medications has been **withdrawn** because the client above has:

- [ ] Missed three doses
  (please append a copy of the patient record form)

- [ ] Exhibited unacceptable behaviour
  Including: __________________________

- [ ] Refused to consume the whole dose under supervision

- [ ] Tried to avoid supervision

- [ ] Appeared intoxicated when attending the pharmacy
  Please give details: __________________________

- [ ] Been admitted to hospital

**Further information**

______________________________

**Signature of Pharmacist:** __________________________

**Date:** ________
# Pharmacy Claim Form

**Application for payment in respect of Supervised Methadone and Buprenorphine Consumption**

**Claim for the Month of ______________________**

Payment will be based on the total number of monthly supervised doses.

I declare that for the above month:-

a) The doses were supervised as listed below and marked M or B (Methadone/Buprenorphine)

b) There is a written procedure for locums on supervision arrangements

c) The service complies with the scheme Service Specification

| Client Initials | DOB | M/B* | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | Total |
|----------------|-----|------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|
|                |     |      |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | |
|                |     |      |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | |
|                |     |      |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | |
|                |     |      |   |   |   |   |   |   |   |   |   |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    |    | |

*Please place an ‘M’ to indicate methadone or ‘B’ to indicate Buprenorphine.
Failure to distinguish between the two may result in all payments being made at the lower methadone rate.
Below each numbered column please place a tick (√) to indicate supervision or a cross (x) to indicate no supervision has taken place.
Name of Pharmacist providing Supervised Consumption Services  ............................................................
Signed ................................................................................. Date ........................................ (The form will be returned if not signed & dated)

Pharmacy Stamp + OCS Code
Changes in the provision of Supervised Consumption of Methadone or Buprenorphine by Accredited Pharmacists

Pharmacy name: ____________________________________________________________

Pharmacy address: ________________________________________________________

______________________________________________________________

Please complete the relevant section:

Section A – newly qualifying pharmacists

____________________ has now _______ completed ____________________________

(Pharmacists name) (date) (Course name and provider)

Section B – change in accredited pharmacist

The Supervised Consumption of Methadone and Buprenorphine Scheme at _____________

_______________ will henceforth _________ be administered by _________________

(Pharmacy name) (date) (name)

who has completed ____________________________

(Course name, provider and date of completion)

Section C – Temporary / Interim arrangements

Between ___________ and __________ the Supervised Consumption of Methadone and

Buprenorphine Scheme will be provided by _______________________.

This pharmacist has/has not completed an accredited course. (delete as appropriate)

Complete if appropriate ____________________________

(Course name, provider and date of completion)

This pharmacist must be aware of the Standard Operating Procedures for the scheme.

Section D – to be completed for any other changes to the scheme.

Please explain any other changes to the implementation of the scheme by trained pharmacists.

________________________________________________________________________

________________________________________________________________________

Please send to: The named contact advised by Lancashire Commissioning Support Unit (CSU)
who are acting on behalf of Blackburn with Darwen Borough Council
Additional Information

Clinical Guidelines

A full copy of the ‘Drug Misuse and Dependence – Guidelines on Clinical Management’ can be found at:


Guidance for the Use of Buprenorphine for the Treatment of Opioid Dependence in Primary Care

- RCGP & SMMGP (Updated Oct 2004)
These are the new guidelines that are intended to aid GPs in the use of buprenorphine as a substitute medication for opioid dependence for maintenance and detoxification. Includes main document, Patient Information Sheet, and Summary Sheet.

Copy enclosed for your information

Medico-legal aspects

The Royal Pharmaceutical Society of Great Britain provides guidance on all legal aspects and standards for professional indemnity, both of which can be found in the latest edition of ‘Medicines, Ethics, and Practice’.
http://www.rpsgb.org.uk/